JPRN-jRCTs042200053进行中（未招募）4 期
A multicenter, single arm, open-label trial of prasugrel monotherapy after PCI with the new-generation thin-strut biodegradable polymer everolimus-eluting SYNERGY stent in consecutive patients with chronic coronary syndrome or non-ST-elevation acute coronary syndromes. - ASET-JAPA
Muramatsu Takashi0 个研究点目标入组 400 人开始时间: 2020年10月22日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Successful PCI with optimal acute stent implantation results (based on local standard of care by angiography and/or findings from intracoronary imaging and on investigators discretion) of one or more everolimus-eluting SYNERGY stent(s). Typically, optimal acute coronary stenting result is a combination of successful stent implantation at the target lesion with absence of significant residual diameter stenosis (<20 percent), no edge dissection, no thrombus, no major side branch occlusion, no-reflow, no major stent underexpansion or major stent incomplete apposition.
- •2.Everolimus-eluting SYNERGY stent implantation was performed to treat:
- •a) patients with at least one stenosis (angiographic, visually determined de novo
- •lesions with >=50 percent DS) in at least one major epicardial territory (LAD and/or side branch, CX and/or side branch, RCA and/or side branch) with a vessel size between 2.25 mm and 5.0 mm in diameter supplying viable myocardium;
- •b) Non-acute coronary disease, with normal cardiac troponin values prior to the PCI procedure, and evidences of myocardial ischemia by symptoms or non-invasive testing (e.g. treadmill exercise test, radionuclide scintigraphy, stress echocardiography);
- •c) patients anatomical SYNTAX Score <23 prior to everolimus-eluting SYNERGY stent implantation;
- •3.Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Certified Clinical Research Review Board.
- •1.Patients with diagnosed Non ST-elevation acute coronary syndrome
- •2.Patients anatomical SYNTAX Score <23 prior to everolimus-eluting SYNERGY stent implantation;
- •3.Patient has been informed of the nature of the study and agrees to its requirements and has provided written informed consent as approved by the Certified Clinical Research Review Board.
- •4.Successful primary PCI with optimal acute stent implantation results (based on local standard of care by angiography and/or findings from intracoronary imaging and on investigators discretion) of one or more everolimus-eluting SYNERGY stent(s). Typically, optimal acute coronary stenting result is a combination of successful stent implantation at the target lesion with absence of significant residual diameter stenosis (<20 percent), edge dissection, thrombus, major side branch occlusion, no-reflow at the end of the procedure, major stent under expansion or major stent incomplete apposition and absence of persistent chest pain after the procedure.
- •5.Everolimus-eluting SYNERGY stent implantation was performed to treat:
- •a) patients with at least one stenosis (angiographic, visually determined de novo lesions with >=50 percent DS) in at least one major epicardial territory (LAD and/or side branch, CX and/or side branch, RCA and/or side branch) with a vessel size between 2.25 mm and 5.0 mm in diameter supplying viable myocardium;
- •6.Patient is free of angina symptoms at the end of PCI procedure.
排除标准
- •1.Under the age of 20 years;
- •2.Unable to give Informed Consent;
- •3.Females of child-bearing potential unless negative pregnancy test at screening and willing to use effective contraception (i.e. established use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or barrier methods of contraception with spermicide or sole male partner with prior vasectomy and confirmed absence of sperm in ejaculate) for the duration of treatment with study medication.
- •4.Female who is breastfeeding at time of enrolment;
- •5.If a stent other than the Synergy stent is implanted at the time of Index PCI.
- •6. Patients scheduled for staged PCI or surgical intervention after enrollment.
- •7.Previous PCI with any non-SYNERGY stents in the last 6 months;
- •8. Patients presenting with acute coronary syndromes
- •9.Patients with a history of acute coronary syndromes within 12 months
- •10.Patient with following lesion characteristics prior to everolimus-eluting SYNERGY stent implantation:
- •- Saphenous or arterial graft
- •- in-stent (re)stenosis;
- •11. Patients with a history of stent thrombosis
- •12.Concomitant cardiac valve disease requiring invasive therapy (reconstruction or replacement);
- •13.Atrial fibrillation or other indication for oral anticoagulant therapy;
- •14.Known allergy to aspirin, prasugrel or diagnosed lactose intolerance;
- •15.Patients presenting with acute heart failure
- •16.Patients presenting with active pericardial myocarditis
- •17.Patients with known cardiomyopathy
- •18.Patinets treated with hemodialysis;
- •19.Treatment in the last 10 days or requirement for ongoing treatment with a strong CYP3A4 inhibitor or inducer;
- •20.Previous stroke or transient ischemic cerebrovascular accident (TIA);
- •21.Previous history of intracranial haemorrhage or other intracranial pathology associated with increased bleeding risk;
- •22.Haemoglobin <10 g/dL or other evidence of active bleeding;
- •23.Peptic ulceration documented by endoscopy within the last 3 months unless healing proven by repeat endoscopy;
- •24.Any other condition deemed by the investigator to place the patient at excessive risk of bleeding with prasugrel;
- •25.Participation in another trial with an investigational drug or device;
- •26.Co-morbidity associated with life expectancy less than 1 year;
- •27.Assessment that the subject is not likely to comply with the study procedures or have complete follow-up;
- •28.Known drug or alcohol dependence within the past 12 months as judged by the investigator.
- •29.Patients deemed inappropriate by the physician
- •1.Under the age of 20 years;
- •2.Unable to give Informed Consent;
- •3.Females of child-bearing potential unless negative pregnancy test at screening and willing to use effective contraception (i.e. established use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or barrier methods of contraception with spermicide or sole male partner with prior vasectomy and confirmed absence of sperm in ejaculate) for the duration of treatment with study medication;
- •4.Female who is breastfeeding at time of enrolment;
- •5.Patients treated with everolimus-eluting SYNERGY stent(s) but who also concomitantly received any other non-study stent at the same procedure (all lesions must be treated with everolimus-eluting SYNERGY stent);
- •6.Patients scheduled for staged PCI or surgical intervention after enrollment
- •7.Previous PCI with any no
研究者
相似试验
进行中（未招募）
1 期
Study of Efficacy and Safety of Twice Daily Oral iptacopan in Adult PNH Patients who are naïve to complement inhibitor therapyParoxysmal Nocturnal Hemoglobinuria (PNH)MedDRA version: 21.1Level: PTClassification code 10034042Term: Paroxysmal nocturnal haemoglobinuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2020-003172-41-CZovartis Pharma AG40
进行中（未招募）
1 期
Study of Efficacy and Safety of Twice Daily Oral iptacopan in Adult PNH Patients who are naïve to complement inhibitor therapyEUCTR2020-003172-41-FRovartis Pharma AG40
进行中（未招募）
1 期
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients who are naïve to complement inhibitor therapy.Paroxysmal Nocturnal Hemoglobinuria (PNH).MedDRA version: 21.1Level: PTClassification code 10034042Term: Paroxysmal nocturnal haemoglobinuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2020-003172-41-ITOVARTIS PHARMA AG40
进行中（未招募）
1 期
se of Fostemsavir in HIV-1 infected children and adolescents with Multi Drug-Resistant virusHIV-1 infection in children and adolescents with Multi Drug-Resistant virusMedDRA version: 20.1Level: LLTClassification code 10020447Term: Human immunodeficiency virus type I infection with other conditionsSystem Organ Class: 100000004862EUCTR2020-001029-30-ESFondazione Penta ONLUS60
尚未招募
不适用
A Prospective, Randomized, Multicenter Trial of Pregabalin and Celecoxib for Lumbar Spinal Stenosisumbar Spinal StenosisJPRN-UMIN000007419Department of Orthopedic Surgery Kobe University Graduate School of Medicine80